Taf Spray 28.5 Mg/G Cutaneous Spray, Solution
Issued: January 2015
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
TAF SPRAY 28.5 mg/g Cutaneous Spray, Solution
Denmark, Sweden, Finland:
Taf vet. 28.5 mg/g Cutaneous Spray, Solution
Denicol SPRAY 28.5 mg/g Cutaneous Spray, Solution
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 g contains:
Thiamphenicol 28.5 mg
Curcumine (E100) 0.5 mg
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Cutaneous spray, solution.
Clear yellow solution.
4. CLINICAL PARTICULARS
4.1 Target species
Horses, cattle, goats, sheep, pigs, mink, rabbits.
4.2 Indications for use, specifying the target species
- Treatment of superficial wound infections caused by micro-organisms sensitive to thiamphenicol.
In cattle, goats and sheep:
- Treatment of infections of the claw and hoof such as foot rot, interdigital dermatitis, digital dermatitis caused by micro-organisms sensitive to thiamphenicol.
Do not use in known cases of hypersensitivity to the active substance or to any of the excipients. See also section 4.11.
4.4 Special warnings for each target species
Clean the affected area thoroughly before spraying. After administration of the product the animal should be kept on dry ground for at least one hour.
4.5 Special precautions for use
Special precautions for use in animals
Protect the eyes when spraying in the vicinity of the head. The animal should be prevented from licking the treated area, or treated areas on other animals.
Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies.Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacterial resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In cases of accidental eye contact, this product may cause irritation. The use of eye protection (such as safety glasses) is recommended. If irritation occurs, seek medical advice and show the label or package leaflet to the physician.
Asthma and rhinitis may occur following inhalation. Do not inhale vapours. Apply the product in the open air, or in a sufficiently ventilated area.
This product can be toxic when ingested.
Contact with the treated area should be avoided and children should not be allowed to play with treated pet animals until the application site is dry.
Do not eat, drink or smoke during administration.
Hypersensitivity (allergy) to thiamphenicol may occur rarely. People with a known hypersensitivity to thiamphenicol should avoid contact with the product.
Wash hands after use.
This product is supplied in a pressurised container and is extremely flammable. Do not spray on or near a naked flame or any incandescent material. Use the product away from fire and sources of ignition, sparks, heat and electrical appliances.
4.6 Adverse reactions (frequency and seriousness)
4.7 Use during pregnancy, lactation or lay
The use of the product has not been assessed during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.
4.8 Interaction with other medicinal products and other forms of interaction
4.9 Amounts to be administered and administration route
For cutaneous administration. Shake the container thoroughly before spraying.
Spray the solution on the affected area for 3 seconds (equivalent to approximately 45 mg thiamphenicol) once a day. Treatment can be repeated depending on the healing process, up to 3 consecutive days.
The container should be held at a distance of approximately 15-20 cm from the area to be sprayed. For optimal use, wounds should be cleaned before application.
The spray container is suitable to be used in upright and inverted positions.
Overdose (symptoms, emergency procedures, antidotes), if necessary
4.11 Withdrawal period(s)
Meat and offal:
horses, cattle, goats, sheep, rabbits: zero days.
pigs: 14 days.
Milk: zero hours.
Do not use on the udder of lactating animals if their milk is intended for human consumption.
5. PHARMACOLOGICAL PARTICULARS
Pharmacotherapeutic group: antibiotic for dermatological use, other antibiotic
5.1 Pharmacodynamic properties
Thiamphenicol is a broad-spectrum antimicrobial agent, structurally similar to chloramphenicol. It is bacteriostatic for both Gram-positive and Gram-negative bacteria and acts by blocking the protein synthesis.
The most common mechanism of resistance to thiamphenicol is acquired by microorganisms via a plasmid-encoded acetyltransferase that inactivates the drug. Cross-resistance of thiamphenicol with chloramphenicol is complete in bacteria which possess chloramphenicol acetyltransferases (CATs). Acetylation of the hydroxyl groups by CATs prevents drug binding to the 50S ribosomal subunit. There are also other mechanisms of resistance, such as efflux systems, inactivation by phophotransferases, and mutation of the target site or permeability barriers. The CAT genes are commonly found on plasmids and most of these plasmids carry one or more additional resistance genes.
5.2 Pharmacokinetic particulars
The absorption of thiamphenicol following dermal administration is negligible.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Copolymer of vinylpyrrolidone and vinyl acetate (30/70)
6.3 Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.
6.4 Special precautions for storage
Pressurised container.Protect from sunlight and do not expose to temperatures exceeding 50°C. Do not pierce or burn, even after use. Do not spray on or near a naked flame or any incandescent material. Keep away from sources of ignition. Do not smoke when using this product.
6.5 Nature and composition of immediate packaging
Aluminium pressurised containers with epoxy phenolic pigment lacquer of 50, 150, 200, 300 and 400 ml:
Polyamide/polyethylene valve mechanism integrated in aluminium container top
Polypropylene spray nozzle with polyoxymethylene nebuliser.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Eurovet Animal Health B.V.
5531 AE Bladel,
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
13 January 2015
10. DATE OF REVISION OF THE TEXT
Page 1 of 6